Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy
Launched by SMART MEDICAL SYSTEMS LTD. · Aug 4, 2013
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
This is a multicenter, two-arm, randomized, open-label study intended to compare the detection rate obtained by performing G-EYE™ high definition colonoscopy vs. the detection rate obtained by performing high definition standard colonoscopy.
The study will enroll 1000 subjects. Consecutive adult subjects who were referred for elective colonoscopy will be asked to enroll into this randomized clinical study if the candidate meets the study inclusion and exclusion criteria.
Subjects will sign informed consent form and undergo randomization. The study includes a run-in preliminary phase of 27...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients over 50 years old
- • 2. Referred to colonoscopy for screening, following positive FOBT testing, change of bowel habits or for surveillance colonoscopy (history of adenoma resection).
- • 3. The patient must understand and provide written consent for the procedure.
- Exclusion Criteria:
- • 1. Subjects with inflammatory bowel disease;
- • 2. Subjects with a personal history of polyposis syndrome;
- • 3. Subjects with suspected chronic stricture potentially precluding complete colonoscopy;
- • 4. Subjects with diverticulitis or toxic megacolon;
- • 5. Subjects with a history of radiation therapy to abdomen or pelvis;
- • 6. Pregnant or lactating female subjects;
- • 7. Subjects who are currently enrolled in another clinical investigation.
- • 8. Subjects with current oral or parenteral use of anticoagulants
- • 9. Subjects with recent (within the last 3 mounts) coronary ischemia or CVA (stroke)
- • 10. Any patient condition deemed too risky for the study by the investigator
- • 11. Previous colonic surgery (except for appendectomy)
About Smart Medical Systems Ltd.
Smart Medical Systems Ltd. is an innovative healthcare technology company dedicated to enhancing diagnostic and therapeutic procedures through advanced medical devices and software solutions. With a focus on improving patient outcomes and streamlining clinical workflows, the company leverages cutting-edge technology to develop tools that assist healthcare professionals in making informed decisions. Committed to rigorous clinical research and compliance with regulatory standards, Smart Medical Systems Ltd. aims to revolutionize the medical landscape by providing reliable, user-friendly solutions that address critical needs in various medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tübingen, , Germany
New York, New York, United States
Dudley, , United Kingdom
Hyderabad, , India
Netanya, , Israel
Tzrifin, , Israel
Maastricht, , Netherlands
Boston, Massachusetts, United States
Harlev, , Denmark
Mainz, , Germany
Wiesbaden, , Germany
Jerusalem, , Israel
Milan, , Italy
Nijmegen, , Netherlands
Birmingham, , United Kingdom
Patients applied
Trial Officials
Ralf Kiesslich, Prof.
Principal Investigator
Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials